Teva launches generic Uceris
Teva Pharmaceuticals Industries has introduced the generic version of Salix Pharmaceuticals' Uceris (budesonide) extended-release tablets in a 9 mg dosage strength.
Budesonide extended-release tablets are a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.
“The launch of generic budesonide extended-release tablets signals an important addition to Teva’s portfolio,” said Teva executive vice president and head of North America Commercial Brendan O’Grady. “We continue to be focused on bringing affordable generic treatment options to our customers, including those living with chronic, life-long conditions like ulcerative colitis.”
Uceris has a market value of approximately $196 million in the United States, according to IMS data as of May 2018.
Budesonide extended-release tablets are a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.
“The launch of generic budesonide extended-release tablets signals an important addition to Teva’s portfolio,” said Teva executive vice president and head of North America Commercial Brendan O’Grady. “We continue to be focused on bringing affordable generic treatment options to our customers, including those living with chronic, life-long conditions like ulcerative colitis.”
Uceris has a market value of approximately $196 million in the United States, according to IMS data as of May 2018.